The activity of a variety of extracellular signaling factors is tightly regulated by proteins containing A Disintegrin And a Metalloprotease domain (ADAM) metalloproteases through limited proteolysis. Thus, the identification of ADAM substrates may unveil novel components and mechanisms of cell signaling pathways. We report the identification of the transmembrane protein vasorin (VASN), a transforming growth factor-b (TGFb) trap, as a substrate of ADAM17. The metalloprotease efficiently generates a soluble fragment encompassing the extracellular domain of VASN. Despite the importance of TGFb in normal development and tumor progression, the regulation of VASN is completely unknown. Here, we show that only the soluble form of VASN inhibits TGFb and that the secretion of VASN is tightly controlled by ADAM17. Hence, inhibition of ADAM17 leads to the upregulation of TGFb signaling. Adding a new level of complexity to the function of ADAM17, we finally show that, through the cleavage of VASN, the metalloprotease controls TGFb-mediated epithelial-to-mesenchymal transition.
Introduction
Metalloproteases are classified into three large families: proteins containing A Disintegrin And a Metalloprotease domain (ADAMs), ADAMs with thrombospondin motifs and matrix metalloproteases (Kessenbrock et al., 2010) . Initially, metalloproteases were considered collectively as mere extracellular matrix-degrading enzymes. In contrast with this simplistic view, currently, individual metalloproteases are viewed as components of signaling pathways that, through limited proteolysis, regulate the availability and activity of other signaling components, such as growth factors or receptors (Brinckerhoff and Matrisian, 2002) . For example, matrix metalloproteases 2 and 9 have been shown to regulate the activity of transforming growth factor-b (TGFb) by releasing it from the extracellular matrix, where the growth factor is stored in a latent state (Annes et al., 2003) . Similarly, metalloproteases of the ADAM family, particularly ADAM17 and ADAM10, cleave plasma membrane-anchored forms of several epidermal growth factor-like ligands, generating the soluble forms (Arribas and Merlos-Suarez, 2003; Blobel, 2005) . With this view of metalloproteases in mind, researchers are currently looking for novel components and mechanisms that regulate signaling pathways by identifying metalloprotease substrates (Lopez-Otin and Hunter, 2010) .
During tumor progression, transformed cells usurp tissue remodeling programs required for normal development. This is best exemplified by the epithelial-tomesenchymal transition (EMT), which is not only indispensable during morphogenesis but also has a central role in tumor progression (Thiery and Sleeman, 2006) . Epithelial cells frequently display polarization, a characteristic organization of the actin cytoskeleton at the cell cortex and grow as layers tightly bound by specialized plasma membrane structures containing E-cadherin (Zavadil and Bottinger, 2005) . Mesenchymal cells meither have an eptithelial-like polarity nor a subcortical organization of the actin cytoskeleton, and cell-cell contacts between mesenchymal cells are much more restricted (Thiery and Sleeman, 2006) . Carcinoma progression is characterized by an EMT-like process, by which epithelial cells lose many of their characteristics and acquire those of mesenchymal cells.
EMT is triggered by components of the extracellular matrix (Zoltan-Jones et al., 2003) and growth factors such as TGFb or epidermal growth factor (Savagner, 2001) . Thus, metalloproteases regulating the availability of these components may regulate EMT in physiological as well as pathological conditions. Not surprisingly, general metalloprotease inhibitors, such as BB-94, prevent EMT in vitro and in vivo (Acloque et al., 2009) , although the mechanism is far from clear.
Furthermore, as some metalloproteases are frequently overexpressed in tumors, it is likely that they may have a central role in the regulation of EMT in such pathologies.
Here, we use a proteomic approach to identify novel metalloprotease substrates in breast cancer cell lines. One of the novel substrates identified is vasorin (VASN), a type I transmembrane protein initially identified in a screening to isolate novel proteins containing a signal sequence. VASN was shown to attenuate TGFb signaling by sequestering the growth factor, and its expression was found restricted to aorta, kidney and placenta (Ikeda et al., 2004) . The mechanisms or factors regulating the anti-TGFb function of VASN are completely unknown.
As shown in the present report, and in contrast with its assumed restricted expression pattern, VASN is expressed in various breast cancer cell lines. Using cells that are genetically deficient in ADAM17, we show that the lack of this metalloprotease impairs the proteolytic shedding of the extracellular domain of VASN. Genetic or chemical inhibition of VASN cleavage boosts the signals transduced by TGFb, showing that the soluble form of VASN, and not the transmembrane form, is responsible for the regulation of TGFb signaling. Finally, we show that expression of VASN, at levels lower than that found in breast cancer cells, efficiently prevents the EMT induced by TGFb in a model cell line. These results indicate that, through the cleavage of VASN, ADAM17 functionally controls TGFb signaling.
Results
Identification of VASN as a metalloprotease substrate in breast cancer cells To identify novel metalloprotease substrates through a non-biased approach, we used stable isotope labeling with amino acids in cell culture (SILAC)-based proteomics. Briefly, we cultured breast cancer MCF7 cells in the presence of arginine and lysine labeled with heavy isotopes or the unlabeled natural amino acids. Cells labeled with heavy isotopes were treated with the inhibitor BB-94, which prevents the cleavage of most metalloprotease substrates analyzed to date (Arribas and Borroto, 2002) , and the conditioned media of control cells and cells treated with the metalloprotease inhibitor were mixed 1 to 1. Typically, metalloprotease substrates are glycosylated (Guo et al., 2002) . Thus, we purified glycoproteins from the mixture of conditioned media by wheat germ agglutinin chromatography. Purified glycoproteins were subjected to SDS-polyacrylamide gel electrophoresis (PAGE) and, after separation, the gel was cut horizontally into slices. The resulting gel segments were individually processed (see Materials and methods) to identify peptides by mass spectrometry. The relative abundance of the peptides identified in the conditioned media of control cells and cells treated with the metalloprotease inhibitor was determined on the basis of their heavy/light ratios.
Two peptide pairs corresponding to the extracellular domain of the type I transmembrane protein VASN, a modular protein containing several domains (Figure 1c ), were identified in the conditioned media. The signal of the heavy forms of these peptides, deriving from the conditioned media of cells treated with BB-94 (Figure 1b) , was much lower than their corresponding light forms (control cells), making this protein a metalloprotease substrate candidate.
To validate the results of the SILAC analysis, we analyzed the species of cell-associated and secreted VASN expressed by control MCF7 cells or the same cells treated with BB-94 at different time points. As previously shown (Ikeda et al., 2004) , VASN is expressed as B110 kDa cell-associated protein. A soluble form of B95 kDa accumulated in the extracellular media. The apparent molecular weight of the secreted form of VASN (sVASN) is compatible with a cleavage in the extracellular juxtamembrane region of the full-length molecule that would also generate a transmembrane/cytoplasmic fragment of an estimated molecular weight of B15 kDa. Confirming the results of the SILAC analysis, treatment with BB-94 prevented the production of sVASN, presumably by inhibiting the metalloprotease responsible for the shedding of its extracellular domain.
Initially, the expression of VASN was thought to be restricted to aorta, kidney and placenta (Ikeda et al., 2004) . However, although at variable levels, both the cell-associated and soluble forms of VASN were readily detected in all breast cancer cell lines that were analyzed. Thus, the expression and cleavage of VASN is a common feature of the analyzed breast cancer cells.
The sVASN regulates TGFb signaling
The initial characterization of VASN showed that, when overexpressed in CHO cells, it inhibits TGFb signaling by trapping the ligand (Ikeda et al., 2004) . However, the relative contribution of the transmembrane and secreted forms of VASN, and thus the functional relevance of the cleavage by metalloproteases, has not been analyzed.
Parental CHO cells express nearly undetectable levels of cell-associated VASN, but sVASN is detectable, indicating that the activity of the metalloprotease(s) that cleave(s) VASN is high in these cells. In agreement with the report by Ikeda et al. (2004) , overexpression of VASN leads to the impairment of the TGFb response, as judged by the lower levels of pSmad2, a substrate of the type I receptor for TGFb (Heldin et al., 1997) , in cells treated with TGFb1. Also, in agreement with the initial characterization of VASN, the inhibition of signaling is likely mediated by the trapping of TGFb, as we showed the presence of the cytokine in immunoprecipitates of soluble VASN (Supplementary Figure S1) . Confirming that VASN acts as TGFb trap, treatment of cells with high concentrations (4100 pM) of TGFb overcame the effect of VASN (data not shown).
As a first approximation to determine the functional relevance of the shedding of VASN, we analyzed TGFb signaling in cells treated with BB-94. The metalloprotease VASN is cleaved by ADAM17 BB-94 targets many metalloproteases of ADAM, ADAMs with thrombospondin motifs and matrix metalloprotease families. However, a large number of the ectodomain-shedding events, similar to that described here for VASN, are carried out by ADAM17 (Arribas and Borroto, 2002) . Therefore, to identify the metalloprotease(s) that cleave(s) VASN, we started by using cells genetically defective for ADAM17.
M2 is a mutant cell line derived from CHO cells that expresses ADAM17, bearing an inactivating mutation (Villanueva de la Torre et al., 2004) . This mutation prevents the removal of the prodomain of ADAM17, which inhibits the proteinase activity in cis (Borroto et al., 2003) . As a result, M2 cells only express inactive proADAM17 (Borroto et al., 2003; Villanueva de la Torre et al., 2004; Figure 3a) .
Compared with CHO cells, M2 cell mutants express very low levels of endogenous sVASN (Supplementary ADAM17 regulates TGFb through the cleavage of VASN J Malapeira et al Figure S2 ). This result indicates that ADAM17 is required for the shedding of VASN or, alternatively, that, compared with parental CHO cells, M2 cells express lower levels of VASN. To distinguish between these possibilities, we transiently transfected CHO and M2 cells with a vector encoding VASN. As shown in Figure 3b , although the levels of expression of cellassociated VASN were comparable, the levels of soluble VASN were approximately fivefold lower in the media conditioned by M2 cells. Transfection of wild-type ADAM17 rescued the defect in M2 cells (Figure 3b and Supplementary Figure S2) , confirming the role of the metalloprotease in the shedding of VASN. It should be noted that, although very low compared with that of ADAM17, some proteolytic activity with the ability to cleave VASN is retained in M2 cells (Figure 3b ).
Therefore, in addition to ADAM17, other proteases are endowed with the ability to cleave VASN.
The substrate specificity of ADAM metalloproteases may depend on the cellular context (Overall and Blobel, 2007) . To extend the results obtained with CHO cells, we compared the shedding of VASN in control MCF7 cells with that in the same cells expressing small hairpin RNAs targeting ADAM17 (previously characterized in the study by Esselens et al. (2008) ; Figure 3c ). The results of this analysis confirmed the participation of ADAM17 in the shedding of VASN (Figure 3d ).
ADAM17 regulates TGFb signaling
The results presented so far indicate that ADAM17 regulates the TGFb pathway through the cleavage of (Figure 4a) . Importantly, TGFb signaling in M2 cells remained unchanged upon treatment with BB-94 (Figure 4a) , showing that the effect of BB-94 on CHO cells is due to the inhibition of ADAM17 and not other metalloproteases targeted by BB-94.
To extend these results, we compared pSmad2 levels in control MCF7 treated with TGFb with that in ADAM17 knockdown MCF7 cells. As shown in Figure 4b , and confirming the role of the metalloprotease on the regulation of TGFb signaling, knockdown MCF7 cells also showed an increased responsiveness to TGFb.
To analyze the effect of the downmodulation of VASN, we used MDA-MB-231 cells that express detectable levels of VASN ( Figure 1e ) and are highly transfectable. In addition, treatment of these cells with BB-94 sensitizes them to the growth inhibition induced by TGFb (Supplementary Figure S4) , indicating that, also in these cells, VASN may regulate TGFb signaling. Transfection of these cells with small interfering RNA (siRNA) specific for VASN led to an 80% reduction in the levels of sVASN (Figure 4c ). In contrast to cells treated with scrambled siRNAs, the response of cells treated with siRNAs targeting VASN to TGFb was not modified by BB-94 (Figure 4d and data not shown). Thus, the effect of the metalloprotease inhibitors on the signaling by TGFb requires intact ADAM17 (Figure 4a ) and VASN (Figure 4d ). sVASN regulates TGFb-induced EMT TGFb induces EMT in a variety of epithelial cells via Smad-dependent and -independent pathways. The hallmarks of EMT include reorganization of the actin cytoskeleton, increased fibronectin expression and loss of the cell adhesion molecule E-cadherin, which forms adherens junctions between epithelial cells (Zavadil and Bottinger, 2005) .
A459 alveolar epithelial cells have a characteristic epithelial morphology with a characteristic accumulation of cortical actin ( Figure 5b ). As previously shown (Kasai et al., 2005) , TGFb1 induced a dose-dependent EMT, as judged by the loss of E-cadherin, remodeling of the actin cytoskeleton and increased levels of fibronectin (Figures 5a and b) . The levels of VASN expressed by A459 cells are threefold lower than those in MCF7 cells, making them an appropriate model to functionally analyze the effect of VASN expression on TGFb signaling.
As expected, treatment of A549 cells with BB-94 prevented the shedding of VASN (Figure 5c ). Confirming the results with CHO and MCF7 cells, overexpression of VASN resulted in the attenuation of TGFb signaling (Figure 5d ). Concomitantly, VASN overexpression interfered with the EMT as shown by the (Figure 5e ), indicating that the production of sVASN is required for its TGFb inhibitory activity. To confirm that the effect of BB-94 is mediated by the inhibition of the production of sVASN, we repeated the treatment with the metalloprotease inhibitor in media conditioned by A549 cells transfected with VASN (that is, enriched in sVASN). The presence of sVASN completely prevented the effect of BB-94, demonstrating that the cleavage of VASN is a crucial step in the regulation of TGFb signaling ( Figure 6 ).
Discussion
TGFb inhibits the proliferation of normal epithelial cells. During carcinoma progression, malignant cells lose this inhibitory response. Several mechanisms contribute to overcome the tumor suppressor activities of TGFb, including the overexpression of ligand traps that impede the binding of TGFb to its receptors (Massague, 2008) . These ligand traps include latencyassociated protein, which sequesters TGFb in a complex anchored to the extracellular matrix by the latent TGFb-binding proteins; Hyytiainen et al., 2004) . In contrast to its anti-tumorigenic activity during the initial stages of tumorigenesis, TGFb favors the malignant progression and metastasis in advanced tumors through several mechanisms, including the induction of EMT, (Muraoka-Cook et al., 2005) . In this scenario, ligand traps are considered anti-tumorigenic.
Although VASN was initially identified as a TGFb trap (Ikeda et al., 2004) , it has remained poorly characterized probably because its was thought to be expressed in a very restricted manner. However, as shown here, the expression of VASN is frequent in breast cancer cells and other cell types, such as CHO or A459 cells, indicating that it is a regulator of TGFb far more general than originally proposed.
Regulation of protein function by ADAM17
The exquisite control of the anti-TGFb activity of VASN by ectodomain shedding provides an excellent example of how proteolysis by ADAM17 modulates protein function (Figure 6 ). In fact, the inhibition of the shedding of VASN by BB-94 completely overcomes its effect on TGFb signaling. This observation is particularly relevant in CHO cells, where the effect of BB-94 is mediated exclusively by ADAM17. The mechanism behind this effect is unknown; conceivably, the affinity of the transmembrane form of VASN for TGFb may be lower than that of sVASN. Alternatively, the levels of transmembrane VASN may not be sufficient to effectively sequester TGFb. In this respect, it should be noted that the levels of sVASN accumulated in the media conditioned by MCF7 cells for 48 h are 3-4-fold higher than that of transmembrane VASN. Furthermore, longterm treatment with BB-94 does not lead to a substantial accumulation of endogenous cell-associated VASN (for example, Figure 1d ), indicating that, if not cleaved by ADAM17, VASN rapidly turns over. Supporting this conclusion, the turnover rate of VASN in cells treated with BB94 is similar to that in control untreated cells.
The control of the TGFb pathway by ADAM17 Active TGFb binds to the type II TGFb receptor (TbRII). Then, the type I TGFb (TbRI) receptor is recruited, allowing TbRII to transphosphorylate and activate the TbRI kinase, which, in turn, phosphorylates Smad2 and Smad3. Phosphorylated Smads associate with Smad4, translocate to the nucleus and regulate gene transcription (Massague, 2008) . ADAM17 contributes to downregulate TGFb signaling through at least two different but complementary mechanisms. In addition to the VASN-dependent mechanism described here, ADAM17 can inhibit TGFb signaling by cleaving the TbRI (Liu et al., 2009) . Thus, in addition to cleave and activate a ligand trap, ADAM17 depletes the cell surface from one of the components of the TGFb signaling complex. Thus, it appears that the cell has developed a different complementary mechanism to ensure the TGFb signaling upon ADAM17 activation.
VASN, ADAM17 and TGFb in cancer ADAM17 is overexpressed in different tumors, including breast cancer (Arribas and Esselens, 2009) , and VASN is also expressed in all the analyzed breast cancer cell lines. Therefore, ADAM17 likely exerts a profound inhibition of TGFb signaling, particularly in breast cancer cells overexpressing both the metalloprotease and the TGFb trap. This is particularly relevant in breast cancer, where the inhibition of ADAM17 impairs tumor progression in a variety of preclinical models (Kenny and Bissell, 2007) . The anti-tumor effect is likely because ADAM17 regulates TGFb through the cleavage of VASN J Malapeira et al of the ability to cleave transmembrane epidermal growth factor-like growth factors, such as proTGFa (BorrellPages et al., 2003) . In fact, ADAM17 inhibitors are currently being tested in clinical trials (Friedman et al., 2009) . The results presented here reinforce the hypothesis that the inhibition of ADAM17 may be an effective antitumor strategy in early stages of tumor progression when ADAM17 can exert a dual pro-tumorigenic effect by contributing to the overproduction of ligands of the epidermal growth factor receptor pathway (Blobel, 2005) and by downregulating the tumor suppressor TGFb pathway via the generation of soluble VASN.
However, because of the highly contextual activity of TGFb, it is more difficult to predict how the inhibition of ADAM17 may impact later phases of cancer progression, namely tumor invasion and metastasis, when TGFb tends to favor malignant progression. In such a context, the inhibition of ADAM17 and the subsequent immobilization of VASN will boost TGFb signaling and could contribute to EMT and tumor invasion.
Materials and methods

Plasmids and siRNAs
The complementary DNA encoding human VASN was kindly provided by Dr Yuichi Ikeda (HHMI/Department of Molecular Genetics, University of Texas Southwestern Medical Center, Dallas, TX, USA). The siRNA targeting human VASN was purchased from Santa Cruz (Santa Cruz, CA, USA).
Antibodies and inhibitors
Primary antibodies. The rabbit polyclonal antibody anti-ADAM17 was from Millipore (Billerica, MA, USA). The goat polyclonal antibody against the extracellular domain of VASN was from R&D Systems (Minneapolis, MN, USA). The rabbit monoclonal antibody against phospho-Smad2 (serine 465/467) and the mouse monoclonal antibody against Smad2 were from Cell Signalling (Beverly, MA, USA). The mouse anti-Ecadherin antibody was from BD Biosciences (San Jose, CA, USA). The rabbit anti-fibronectin antibody was from SigmaAldrich (St Louis, MO, USA). Rhodamine-conjugated phalloidin was from Invitrogen (Frederick, MD, USA). BB-94 was provided by British Biotech Pharmaceuticals, Ltd (Oxford, UK).
Cells and transfections
MCF7, SK-BR-3, MDA-MB-416, MDA-MB-631, BT474, MDA-MB-231 and CHO were obtained from the American Type Culture Collection. A549 cells were kindly provided by Dr Joan Seoane. The characterization of the MCF7 cell lines stably transfected with a scrambled small hairpin RNA or an small hairpin RNA targeting ADAM17 has been previously published (Esselens et al., 2008) . M2 cells have been previously characterized in studies by Borroto et al. (2003) and Villanueva de la Torre et al. (2004) .
Transient and stable transfections were performed using the Fugene-6 transfection reagent according to the manufacturer's instructions (Roche Diagnostics, Indianapolis, IN, USA). SILAC MCF7 cells were seeded in SILAC Dulbecco's modified Eagle medium medium (GIBCO, Carlsbad, CA, USA) supplemented with dialyzed serum (amino acid free) and normal or isotopically labeled amino acids (Esselens et al., 2008) . Briefly, cells were incubated with heavy or light amino acids for a total of 11 days, corresponding to six cell doublings.
C
14 N lysine and 12 C 14 N arginine 'light' amino acids were used for the control (ÀBB-94) condition, whereas 13 C 6 14 N lysine and 13 C 6 15 N 4 arginine 'heavy' amino acids for the BB-94-treated condition. During the final 48 h, to reduce protein background, serum was removed and 10 mM of BB-94 was added to cells labeled with heavy isotopes. We did not observe differences (41%) in cell number between treated and untreated situations. Then, the supernatants of control and BB-94-treated cells were mixed 1:1 and incubated overnight at 4 1C with wheat germ agglutinin-agarose beads (1 ml of stirred suspension per ml of conditioned medium). Glycoproteins were eluted by rotating for 2 h at 4 1C with 4 ml of 0.5 M N-acetylglucosamine in 10 mM HEPES (pH 7.5)-0.15 M NaCl buffer. The glycoprotein solutions were then quantified and concentrated 40-fold by ultrafiltration (Amicon Ultra-4, 5 kDa cutoff; Millipore, Carrigtwohill, Ireland), Urea was then added to the concentrated protein solution to a final 8 M concentration and pH was adjusted to 8.5. Proteins were reduced by addition of 50 mM dithiothreitol (DTT) and incubation for 30 min at room temperature, and then carbamidomethylated with 125 mM iodoacetamide for 1 h at room temperature. The protein mixture was then purified by a modified acetone-trichloroacetic acid precipitation (2D-CleanUp kit; GE Healthcare, Waukesha, WI, USA). The resulting protein pellet was resuspended in 40 ml of SDS-PAGE loading buffer and subjected to one dimensional electrophoresis on a 10% polyacrylamide SDS gel.
The SDS-PAGE gel was cut into 20 horizontal slices and individual slices were digested using modified porcine trypsin (Promega, Madison, WI, USA). Digests were analyzed on an Esquire Ultra IT mass spectrometer (Bruker, Bremen, Germany), coupled to a nano-HPLC system (Ultimate, LC Packings, Amsterdam, Netherlands). Peptide mixtures were initially concentrated on a 300 mm i.d., 1 mm PepMap nanotrapping column and subsequently loaded onto a 75 mm i.d., 15 cm PepMap nanoseparation column (LC Packings). An acetonitrile gradient (0-60% B in 150 min, where B is 80% acetonitrile (ACN), 0.1% formic acid in water; flow rate B300 nl/min) was used to elute the peptides through a PicoTip emitter nanospray needle (NewObjective, Woburn, MA, USA) onto the nanospray ionization source of the IT mass spectrometer. MS/MS fragmentation (1.9 s, 100-2800 m/z) of two of the most intense ions was carried out, as detected from a 1.2 s mass spectrometry survey scan (310-1500 m/z), using a dynamic exclusion time of 1.2 min for precursor selection and excluding single-charged ions. An automated optimization of MS/MS fragmentation amplitude, beginning at 0.60 V, was used.
Protein identification and data analysis. Data processing for protein identification and quantification was performed using WARP-LC (Bruker), a software platform integrating liquid chromatography (LC)-MS run data processing, protein identification through database search of MS/MS spectra and protein quantification based on the integration of the chromatographic peaks of MS extracted ion chromatograms for each precursor. Proteins were identified using Mascot (Matrix Science, London, UK) to search the SwissProt 57.0 database, restricting the search to human proteins (428,650 sequences). MS/MS spectra were searched with a precursor mass tolerance of 1.5 Da, fragment tolerance of 0.5 Da, trypsin specificity with a maximum of one missed cleavage, carbamidomethylation set as fixed modification and methionine oxidation and the corresponding lysine and arginine SILAC labels as variable modifications. Positive identification criterion was set as an individual Mascot score for each peptide MS/MS spectrum higher than the corresponding homology threshold score. For protein quantification, (H/L) ratios were calculated by averaging the measured (H/L) ratios for the observed peptides, after discarding outliers. For selected proteins, quantification data obtained from the automated WARP-LC analysis were manually reviewed.
Western blots
Cells were scraped in lysis buffer and total protein in the lysates was quantified using the Bio-Rad (Hercules, CA, USA) Dc Protein Assay according to the manufacturer's instructions. In all, 50 mg of total protein were loaded in 10% SDS-PAGE. After electrophoresis, proteins were transferred to nitrocellulose membrane (Bio-Rad) and checked by Ponceau red stain. Primary antibodies were incubated with the corresponding horseradish peroxidase-conjugated secondary antibodies and detected with ECL.
To analyze VASN and sVASN, 100 mm dishes of subconfluent cells were washed and incubated in serum-free Dulbecco's modified Eagle medium for different periods of time. Then media were harvested and cells lysed as described in the study by Pedersen et al. (2009) . Glycoproteins from the conditioned media and from the clarified cell lysates were purified with agglutinin (wheat germ agglutinin) chromatography, loaded into 10% SDS-polyacrylamide gel, transferred to nitrocellulose membranes and blotted with anti-VASN antibody.
To analyze pSmad2 levels, cells were plated in 100 mm dishes in Dulbecco's modified Eagle medium-F12 þ 10% fetal bovine serum. Sub-confluent dishes were washed and incubated with serum-free Dulbecco's modified Eagle medium for 48 h. Then, cells were treated for 3 h with different concentrations of TGFb1. Finally, the cells were lysed and analyzed by western blot. The same membrane was analyzed first with antibodies against pSmad2 and subsequently with anti-Smad2 antibodies. Specific signals in western blots were quantified with ImageJ 1.38 (NIH) software, the levels of pSmad were normalized to the levels of Smad and expressed as fold increase relative to untreated CHO or A549 cells. In the case of MCF7 cells, the results were expressed as fold increase relative to cells treated with 5 pM TGFb, because no specific signal was detected in untreated cells.
Immunofluorescense microscopy A549 cells were fixed and processed for immunofluorescence with anti-E-cadherin and anti-fibronectin antibodies or rhodamine-conjugated phalloidin as previously described. Images were taken using the confocal espectral Olympus FV1000 (Olympus, Center Valley, PA, USA).
